Tango Therapeutics (TNGX) EBT (2020 - 2026)

Tango Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.

• In Q1 2026, EBT fell 14.23% year-over-year to -$45.5 million; the TTM figure through Mar 2026 stood at -$107.3 million (up 18.78% YoY), while the FY2025 annual figure was -$101.6 million, up 21.91% from the prior year.
• EBT was -$45.5 million for Q1 2026 at Tango Therapeutics, down from -$38.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $15.9 million in Q3 2025 to a low of -$45.5 million in Q1 2026.
• Historically, EBT has averaged -$28.6 million across 5 years, with a median of -$29.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: EBT tumbled 450.62% in 2022, then surged 154.53% in 2025.
• A 5-year view of EBT shows it stood at -$29.0 million in 2022, then retreated by 5.88% to -$30.7 million in 2023, then declined by 22.48% to -$37.6 million in 2024, then fell by 3.14% to -$38.8 million in 2025, then declined by 17.29% to -$45.5 million in 2026.
• The last three EBT figures came in at -$45.5 million (Q1 2026), -$38.8 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.